Differential CD4/CD8 subset-specific expression of highly homologous rat Tcrb-V8 family members suggests a role of CDR2 and/or CDR4 (HV4) in MHC class-specific thymic selection. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Differential CD4/CD8 subset-specific expression of highly homologous rat Tcrb-V8 family members suggests a role of CDR2 and/or CDR4 (HV4) in MHC class-specific thymic selection.

Int Immunol. 1999 Mar;11(3):435-44. Unique Identifier : AIDSLINE MED/99236844
Herrmann T; Hofmann K; Nagel NE; Asmuss A; Hunig T; Wonigeit K; Institut fur Virologie und Immunobiologie,; Julius-Maximillians-Universitat Wurzburg, Germany.; herrmann-t@vim.uni-wuerzburg.de


Abstract: Different rat Tcrb haplotypes express either TCR beta variable segment (Tcrb-V) 8.2l or 8.4a. Both V segments bind the mAb R78 but differ by one conservative substitution (L14V) and clusters of two and four substitutions in the complementarity-determining region (CDR) 2 and CDR4 [hypervariable loop 4 (HV4)]. Independently of MHC alleles numbers of R78+ CD4+ cells are lower in Tcrb-V8.2l-expressing than in Tcrb-V8.4a-expressing strains. Expression of R78+ TCR during T cell development, analysis of backcross populations and generation of a Tcrb congenic strain [LEW.TCRB(AS)] define two mechanisms how Tcrb haplotypes affect the frequency of R78+ cells, one acting prior to thymic selection leading to up to 2-fold higher frequency of Tcrb-V8.4a versus Tcrb-V8.2l in unselected thymocytes and another occurring between the TCRlow and the CD4/CD8 single-positive stage. The latter leads to a 50% reduction of frequency of Tcrb-V8.4a CD8+ cells but not CD4+ cells and does not affect either subset of Tcrb-V8.2l cells. A comparison of rat classical class I MHC (RT1.A) sequences and current models of TCR-MHC-peptide interaction suggests that this reduction in frequency of Tcrb-V8.4a CD8 cells may be a consequence of differential selection of Tcrb-V8.2l versus Tcrb-V8.4a TCR by differential binding of CDR2beta to highly conserved areas of C-terminal parts of the alpha helices of class I MHC molecules.
Keywords: JOURNAL ARTICLE Alleles Animal Cell Differentiation Crosses, Genetic CD4-Positive T-Lymphocytes/CYTOLOGY/*IMMUNOLOGY CD8-Positive T-Lymphocytes/CYTOLOGY/*IMMUNOLOGY Female Haplotypes Histocompatibility Antigens Class I/GENETICS/IMMUNOLOGY Major Histocompatibility Complex/*IMMUNOLOGY Models, Immunological Rats Rats, Inbred Strains Receptors, Antigen, T-Cell, alpha-beta/*GENETICS Support, Non-U.S. Gov't T-Lymphocyte Subsets/CYTOLOGY/*IMMUNOLOGY Thymus Gland/CYTOLOGY/*IMMUNOLOGY Variation (Genetics)KWDjournalarticleallelesanimalcelldifferentiationcrosses,geneticcd4-positivet-lymphocytes/cytology/KWDimmunologycd8-positivet-lymphocytes/cytology/KWDimmunologyfemalehaplotypeshistocompatibilityantigensclassi/genetics/immunologymajorhistocompatibilitycomplex/KWDimmunologymodels,immunologicalratsrats,inbredstrainsreceptors,antigen,t-cell,alpha-beta/KWDgeneticssupport,non-uKWDsKWDgov'tt-lymphocytesubsets/cytology/KWDimmunologythymusgland/cytology/KWDimmunologyvariation(genetics)
990930
A9991309

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .